With Shkreli Spike, KaloBios Pharma (KBIO) May Be Overvalued by a Factor of 4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Form 4 KALOBIOS PHARMACEUTICALS For: Nov 16 Filed by: Shkreli Martin
November 18, 2015 4:10 PM EST.FormData { color: blue; background-color: white; font-size: 12px; font-family: Times, serif; } .FormDataR { color: blue; background-color: white; font-size: 12px; font-family: Times, serif; text-align: right; } .SmallFormData { color: blue; background-color: white; font-size: 10px; font-family: Times, serif; } .FootnoteData { color: green; background-color: white; font-size: 10px; font-family: Times, serif; } .FormNumText { font-size: 12px; font-weight: bold; font-family: arial, helvetica, sans-serif; } .FormAttention { font-size: 12px; font-weight: bold; font-family: helvetica; } .FormText { font-size: 12px; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left; } .FormTextR { font-size: 12px; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right; } .FormTextC { font-size: 12px; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center; } .FormEMText { font-size: 12px; font-style: italic; font-weight: normal;... More
